Viswanath Das

13PUBLICATIONS
25CO-AUTHORS
Gene and molecular therapyBiomolecular modelling and designMolecular targetsCheminformatics and quantitative structure-activity relationshipsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Oct 22, 2026
Repurposed catechol-O-methyltransferase inhibitors tolcapone and entacapone preferentially suppress aggregation and seeding of P301 mutant tau in human neuronal models.

|Sep 12, 2026
Design, synthesis, molecular docking and anticancer activity of novel N-(4-(chlorodifluoromethoxy)phenyl)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives.

|Mar 12, 2026
Oncology drug repurposing as a blueprint for Alzheimer's therapy.

Viswanath Das, Marián Hajdúch

|Dec 08, 2025
Design, synthesis, and biological evaluation of novel 3-oxo-2,3-dihydropyridazine derivatives as interleukin-2-inducible T-cell kinase (ITK) inhibitors.

Sudhakar Tangallapalli, Rambabu Gundla, Kalyani Paidikondala

|Aug 27, 2025
Structural and functional insights into the selective inhibition of mutant tau aggregation by purpurin and oleocanthal in frontotemporal dementia.

Alladi Charanraj Goud, Ihor Kozlov, Patricie Skoupilová

|Aug 17, 2025
Hydrophobic residues in the α-synuclein NAC domain drive seed-competent fibril formation and are targeted by peptide inhibitors.

Viswanath Das, Sayed Mostafa Modarres Mousavi, Narendran Annadurai

Pageof 3

Frequent Collaborators

2 joint publications

Bohumír Grüner

2 joint publications

Jan Nekvinda

2 joint publications

Ihor Kozlov

2 joint publications

Roman Kouřil